Patents Act 1990 (Cth)

The Patents Act 1990 (Cth) is the main Commonwealth law governing patents in Australia. It sets out the object of the Act, who may be granted a patent, what counts as a patentable invention, how applications are filed and examined, when patents are granted, how long they last, and how they can be enforced or challenged.

The Act also covers practical commercial issues that matter to businesses, including assignment, co-ownership, registration of interests, infringement by supply, exemptions from infringement, unjustified threats, compulsory licences, revocation, surrender, lapsing, ceasing of patents, the Register of Patents, and the powers of the Commissioner and the courts.

For many businesses, the Act is not just about obtaining a monopoly right. It is also the framework that determines whether a product launch is risky, whether an investor will be comfortable with your IP position, whether a contractor-created invention is actually owned by the company, and whether a competitor can challenge or enforce rights against you.

You are likely to be affected by the Act if your business develops inventions, files patent applications, acquires patented technology, licenses technology, imports technical goods, manufactures products, supplies components, or commercialises a process that may be protected by patent rights. The Act is also relevant if your business is involved in research and development, especially where multiple founders, employees, universities, consultants or contractors contribute to the inventive work.

Businesses are also in scope if they need freedom-to-operate advice before launch. The Act contains infringement provisions, including infringement by supply of products, and court procedures for infringement, revocation and non-infringement declarations. That means a business can be affected even if it never intends to own a patent.

Businesses are usually less directly affected if they operate entirely outside technical invention-based products or processes. Even then, the Act can still become relevant where software, machinery, manufacturing systems, medical technology, imported components or embedded technical features are involved. A business should be cautious about assuming it is outside the patent system simply because it is not a traditional manufacturer.

The Act becomes practically important at several common business moments. The first is when an invention is created. At that point, entitlement, inventorship, confidentiality, novelty, secret use and filing strategy all become important. The Act includes provisions on novelty, inventive step and innovative step, usefulness, secret use, who may be granted a patent, and the filing and priority framework.

The second trigger point is when a business prepares and files an application. The Act deals with general applications, special rules for PCT applications and Convention applications, filing dates, joint applicants, disputes between applicants, complete and provisional pathways, specifications and priority dates. This is the stage where poor drafting or unclear ownership can create long-term problems.

The third trigger point is examination and acceptance. Standard patents move through request for examination, examination and acceptance procedures, and the Act also provides for opposition to grant of standard patents. Businesses should expect scrutiny of the application and should be ready to respond within the relevant procedural framework.

The fourth trigger point is publication and commercial launch. The Act contains rules on publication, public inspection of documents and the effect of publication of a complete specification. Once a business starts selling, importing or supplying products, infringement risk becomes much more immediate.

The fifth trigger point is when rights are being commercialised, challenged or enforced. The Act covers amendments, re-examination, infringement proceedings, revocation, compulsory licences, surrender, lapsing, ceasing of patents, and registration of particulars on the Register.

The Act gives exclusive rights through a patent and sets out who may be granted one. It also deals with assignment, co-ownership and directions to co-owners. For businesses, this means ownership should never be left to assumption. If founders, employees, consultants or related entities are involved, the company should make sure the paper trail matches the intended ownership position.

The Act also establishes the Register of Patents and a system for registration of particulars of patents and related interests. It separately addresses the evidentiary effect of unregistered particulars. In practice, that means businesses should not only sign the right documents but also consider whether the relevant interest should be recorded on the Register.

Key documents often include employment IP clauses, contractor assignment deeds, founder assignment documents, R&D collaboration agreements, exclusive and non-exclusive licence agreements, and any security or mortgage-related consents where amendments are proposed. The Act also refers to persons claiming under assignment or agreement, which reinforces the need for clear written arrangements.

If ownership is unclear, the business may face disputes over entitlement, difficulties in raising capital, problems with enforcement, and reduced value in any sale or licence of the technology. If co-ownership exists, the business should also understand that co-owner issues are specifically dealt with under the Act rather than being left entirely to informal arrangements.

The Act sets out the path from application to acceptance. It includes rules for applications generally, special rules for PCT and Convention applications, filing dates, disputes between applicants, complete applications, specifications, micro-organism deposit issues, and priority dates. For standard patents, the Act provides for request for examination, examination, acceptance, postponing acceptance in some cases, refusal in certain cases and appeal rights in some circumstances.

For businesses, the practical point is that a patent application is not just a form. The specification is central. It defines the invention being claimed and becomes part of the public record. The Act also contains publication rules, including public inspection of documents and some limits on what may be published or inspected. Once material is published, confidentiality is no longer under your control in the same way.

Businesses should also remember that validity is not guaranteed simply because a patent is granted. The Act expressly deals with validity and with matters that do or do not affect validity. That is important both for applicants and for competitors assessing whether a granted patent is strong.

If your business is relying on an Australian filing strategy linked to overseas filings, the PCT and Convention pathways in the Act should be checked carefully. Timing, priority and document requirements can be commercially critical, especially where multiple jurisdictions are involved.

The Act contains separate provisions on the term of standard patents and the term of innovation patents. It also contains a dedicated regime for extension of term of certain standard patents relating to pharmaceutical substances, including application, timing, notification, opposition, grant and calculation provisions.

For businesses, the practical message is that patent duration is not a one-line issue. Standard patent term should be checked against the current Act, and pharmaceutical businesses should separately assess whether the extension of term regime may apply. The Act also states that the patentee’s exclusive rights are limited in certain ways if an extension is granted, and it deals with rights where an extension is granted after the patent expires.

Innovation patents remain relevant because the Act still contains detailed provisions dealing with their grant, term, examination, re-examination, opposition and ceasing. Businesses should treat innovation patents as a legacy and transitional area unless they have confirmed the current filing position. If you are reviewing an older portfolio, receiving a threat based on an innovation patent, or acquiring historic IP assets, these provisions may still matter materially.

Chapter 11 of the Act deals with infringement and infringement proceedings. It includes infringement by supply of products, exemptions for use in or on foreign vessels, aircraft or vehicles, prior use, acts for obtaining regulatory approval of pharmaceuticals, acts for obtaining regulatory approval for non-pharmaceuticals, and acts for experimental purposes. It also covers infringement proceedings, counter-claims for revocation, burden of proof for process patents, relief for infringement and innocent infringement.

This matters to businesses because infringement risk is broader than direct copying. Supplying products that enable infringement can itself be a problem. Equally, some activities may fall within a statutory exemption, but that should be checked carefully against the current wording and the facts.

The Act also provides for non-infringement declarations and for relief in relation to unjustified threats of infringement proceedings. This is important in commercial negotiations. A business that sends aggressive warning letters without a proper basis may create its own legal exposure. On the other side, a business receiving threats may have options beyond simply backing down or waiting to be sued.

Where disputes escalate, the Act also deals with court jurisdiction, appeals, powers of the Federal Court and related procedural matters. Patent disputes often involve validity and infringement together, so businesses should expect that enforcement can trigger a broader challenge to the patent itself.

The Act does not treat a granted patent as untouchable. It includes rules on amendments that are not allowable, amendments by applicants and patentees, amendments directed by the court or Commissioner, and restrictions on recovery in some amendment situations. It also provides for re-examination of standard patents and, separately, examination, re-examination and opposition mechanisms for innovation patents.

The Act further provides for revocation in a number of contexts, including revocation following re-examination and revocation in other circumstances. There are also provisions dealing with surrender of patents and with compulsory licences. For pharmaceutical inventions, the Act contains a separate compulsory licence regime for manufacture and export to eligible importing countries.

For businesses, this means a granted patent can still be attacked, narrowed, amended, surrendered or affected by compulsory licensing mechanisms. If your business is acquiring a patent portfolio, taking a security interest, or entering a major licence, due diligence should include whether the rights are vulnerable to challenge or subject to pending proceedings.

The Act establishes the Register of Patents, inspection rights, evidentiary rules about the Register and documents, and provisions dealing with false entries and rectification. It also deals with withdrawal of applications, lapsing of applications, ceasing of patents and payment of fees. These are not minor administrative details. They directly affect whether rights remain in force and whether third parties can rely on the public record.

Before relying on this page, a business should check the current compilation of the Act, any endnotes and any recent amendments on the Federal Register of Legislation. The compilation notes state that uncommenced amendments are not shown in the text and that modifications by other laws may not appear in the compilation text. That is especially important where your decision depends on current filing options, time limits, extension of term, infringement exemptions or transitional rules.

As a practical matter, businesses should also check whether the relevant patent or application is correctly recorded, whether any assignment or licence particulars should be registered, whether fees have been paid, whether any opposition or court proceeding is on foot, and whether the right has lapsed or ceased. A patent strategy is only as strong as the underlying records and status checks.

This page is based on the Patents Act 1990 (Cth) as compiled and in force on 14 October 2024 according to the Federal Register of Legislation. The compilation notes state that uncommenced amendments are not shown in the text of the compilation, that application, saving and transitional provisions may need to be checked in the endnotes, and that modifications by other laws may not appear in the compilation text.

Because patent law is technical and regularly updated, businesses should check the current Act, the endnotes, and any later amendments before relying on a specific filing pathway, term calculation, exemption, procedural step or enforcement position.